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Translational pharmacologyMonoclonal antibodies (mAbs) are an important
therapeutic class with complex pharmacology and
interdependent pharmacokinetic (PK) and pharma-
codynamics (PD) properties. Understanding the PK
and PD of mAbs and their biological and mechanistic
underpinnings are crucial in enabling their design and
selection, designing appropriate efficacy and toxicity
studies, translating PK/PD parameters to humans,
and optimizing dose and regimen to maximize suc-
cess in the clinic. Significant progress has been made
in this field however many critical questions still
remain. This article gives a brief overview of the
PK and PD of mAbs, factors that influence them,
and areas of ongoing inquiry. Current tools and
translational approaches to predict the PK/PD of
mAbs in humans are also discussed.
Introduction
Monoclonal antibody (mAb) therapeutics are an important
and rapidly growing class of therapeutic agents with over 470
molecules in the clinical pipeline and many more in earlier
stages of drug development [1]. Selecting the right mAb is a
key determinant of its clinical success and depends on early
understanding of its PK/PD and successfully translating it to
humans. Compared to small molecules, biologics such asE-mail address: (kamath.amrita@gene.com)
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mAbs have unique characteristics that make their pharmaco-
kinetics (PK) and pharmacodynamics (PD) quite complex
[2,3]. An integrated understanding of its PK/PD characteris-
tics including exposure at the site of action, target occupancy
and expression of functional pharmacological activity are
important in improving its clinical success [4]. The utility
of translational PK/PD spans different phases of drug devel-
opment and can contribute to target evaluation, design and
selection of candidate molecule with optimal properties, and
dose and regimen selection in preclinical and clinical studies
[5]. Understanding PK/PD of mAbs and factors that impact
them, are essential to achieve these translational goals. This
review describes the PK and PD characteristics of mAbs, and
translational PK/PD approaches to predict human PK/PD.
Pharmacokinetics and pharmacodynamics of mAbs
The mAb therapeutics currently on the market are from the
immunoglobulin G (IgG) isotype such as IgG1, IgG2, and
IgG4, which in general have PK characteristics such as slow
clearance, long half-life, and limited tissue distribution. This
long half-life offers the advantage of less frequent dosing in
patients as compared to small molecules. After intravenous
(IV) administration, typical mAb serum PK profiles areticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Figure 1. Representative PK profiles for mAbs.biphasic with a rapid distribution phase and a slower elimi-
nation phase as shown in Fig. 1. PK properties of mAbs are
unique in that they are dependent on their structure as well as
can be markedly influenced by the biology of their target
antigen, a concept termed as target-mediated drug disposi-
tion or TMDD [6]. Table 1 summarizes the PK characteristics
of mAbs and their absorption, distribution, and clearance
processes are briefly described below.
Absorption
Oral administration for mAbs is precluded mainly due to their
instability in the gastrointestinal tract (denaturation by acid-
ic pH or proteolytic degradation), as well as their limited
intestinal permeability due to their poor lipophility and large
molecular size [2,3]. mAbs are usually administered parenter-
ally, either by IV, subcutaneous (SC), or intramuscular (IM)
injections. Bioavailability after SC administration is quite
variable and can range from 20–95%, and absorption is likely
facilitated via the lymphatic system, however the exact
mechanisms are poorly understood and preclinical models
to predict human bioavailability are not well established
[7,8]. The rate of absorption is slow with maximal plasma76 www.drugdiscoverytoday.comconcentrations observed 1–8 days following SC or IM injec-
tion.
Distribution
The distribution of mAbs is generally limited to the vascular
and interstitial spaces due to its large size and hydrophilicity
[2,9]. Following IV administration, distribution from vascular
space into tissue interstitial space is mainly by convection
(fluid flow from blood to interstitial spaces). Other factors
that influence mAb distribution include diffusion, pinocyto-
sis, receptor-mediated endocytosis, elimination from the tis-
sue, as well as biophysical characteristics of the mAb such as
charge and hydrophobicity [3]. In cases of specific binding to
the antigen, aspects such binding affinity, receptor expres-
sion, and kinetics of receptor turnover and antigen-mAb
binding can impact distribution. The extent of mAb parti-
tioning from circulation into most tissues generally ranges
from 5–15%, except for brain where it is much lower [10].
Compared to normal tissues, distribution in tumors could be
different due to differences in tumor physiology and depen-
dent on target expression and tumor characteristics [11].
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Table 1. PK characteristics of mAbs
Attributes mAb characteristics
Binding  Binding very specific for target antigen
 Binding to FcRn and recycling contributes to long half-life
 Binding to Fcg receptors can result in effector functions
PK/PD  PK usually dependent on biology of target antigen and PD
 Typically biphasic PK profiles with relatively fast distribution phase and slower elimination phase; long half-life
Dose proportionality  Non-linear PK at low doses
 Linear PK at high doses after saturation of target
 mAbs against soluble antigens with low endogenous levels typically exhibit linear PK
Distribution  Distribution usually limited to blood and interstitial spaces
 Partitioning from blood to tissues is typically 5–15%, except for brain where it is much lower
Metabolism  Catabolism by proteolytic degradation into amino acids
Excretion  No renal CL of intact antibody. May be cleared by damaged kidneys. Uncommon if MW >20 kDa
Immunogenicity  Formation of ATAs against mAb could occur
 ATAs could impact PK, PD, efficacy, safety
 Immunogenicity in animals not predictive of humansClearance
Since mAbs are large molecules that are above the glomerular
filtration cut-off threshold, they are primarily eliminated by
proteolytic catabolism that results in smaller peptides and
amino acids that can be reused for new protein synthesis.
Other pathways involved in removal of mAbs are target
mediated clearance, non-specific pinocytosis, and Fc gamma
receptor (FcgR) mediated clearance [2,3]. These complex
clearance pathways of mAbs can be categorized as specific
and non-specific clearance.
Specific or target mediated clearance of mAbs is mediated
by the interaction of the mAb with its target antigen. This
pathway includes binding of mAb to its target antigen lead-
ing to internalization of the antibody-receptor complex in
case of a membrane bound target, and subsequent intracel-
lular protein catabolism. Aspects of target antigen biology
such as whether it is soluble vs. membrane bound, its distri-
bution, expression level, and turnover rate, and whether it
can be down-modulated or upregulated can impact the
specific clearance pathway of mAbs. At low doses, target-
mediated clearance pathways can lead to non-linear PK of
mAbs, until the target is saturated at higher doses, after
which the PK becomes linear as shown in Fig. 1. For soluble
antigens with low endogenous levels, typically linear PK has
been observed across species (e.g., adalimumab against TNF-
a, bevacizumab against VEGF-A), whereas when endogenous
levels are high, non-linear PK has been observed (e.g., oma-
lizumab against IgE) [12–14]. For membrane bound antigens,
typically non-linear PK has been observed until a higher dose
where target is saturated (e.g., cetuximab and panitumumab
against EGFR) [15]. In addition, when target antigen can be
down-modulated or up-regulated by the mAb, it can result in
time dependent PK of the mAb as is seen with rituximab
(anti-CD20 mAb) which causes B-cell depletion and hencedown-modulation of target that results in reduced clearance
upon repeat dosing [15].
Non-specific clearance includes non-specific uptake by the
cell via pinocytosis and subsequent protein catabolism.
Clearance by the non-specific pathway is low and due to
its large capacity is not saturated at typical concentrations
seen with therapeutic mAbs, thereby resulting in linear PK.
Clearance via the non-specific pathway is influenced by
interaction of the Fc region on the mAb with the neonatal
Fc receptor (FcRn), which plays a role in recycling the mAb
back to the cell surface and releasing it into the extracelluar
fluid [16]. Binding of an IgG1 mAb to FcRn is a pH-dependent
process and modulation of this binding has been shown to
impact the clearance of mAbs in both animals and humans
[17–19].
Fc-mediated effector functions such as complement-de-
pendent cytotoxicity (CDC, caused by binding to comple-
ment C1q) or antibody-dependent cell-mediated cytotoxicity
(ADCC, caused by binding to FcgR) can contribute to the
mechanism of action of the therapeutic mAb [20], however
their impact on mAb clearance is not as straight forward. For
both soluble antigens (which form immune complexes with
mAbs that could promote FcgR binding) or membrane bound
antigens (where mAb binding to target antigen could result in
ADCC via FcgR binding), effect of FcgR binding on mAb
disposition may come into play depending on target levels
and relative contribution of FcgR-mediated clearance to total
clearance at the administered dose. For example, Leabman
et al., showed that altered FcgRIIIA binding affinity did not
affect PK for a set of IgG1 mAbs in cynomolgus monkeys in
the linear dose range of those mAbs where target-indepen-
dent mechanisms (i.e., FcRn) dominate clearance [21]. How-
ever, in studies of mAbs against certain target antigens (e.g.,
CD20 or IgE), where mAb binding to FcgR receptors eitherwww.drugdiscoverytoday.com 77
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Figure 2. Framework for translation of PK/PD of mAbs from in vitro and animal data to humans.caused depletion of target cells (e.g., anti-CD20) or clearance
of immune complexes (e.g., anti-IgE), FcgR binding was
shown to impact mAb disposition in the non-linear dose
range [22–24].
Other factors that could impact mAb disposition include
immunogenicity to therapeutic mAbs resulting in develop-
ment of anti-therapeutic antibodies (ATAs), and antibody
properties such as charge, hydrophobicity, glycosylation,
and off-target binding. Isoelectric point and local charge
patches have been shown to influence mAb disposition,
where increase in positive charge of antibodies likely
increases clearance and distribution due to interactions with
negatively charged components on the tissue [25]. Lastly,
patient characteristics such as disease status, demographic
factors, or concomitant medications could also impact mAb
PK/PD [3].
Pharmacodynamics
PD refers to the pharmacological effects elicited in the body
by a drug. For small molecules, PK is usually independent of
PD. However, PK/PD relationships of mAbs are unique due to
the TMDD phenomenon and often lead to mAb PK being
dependent on PD. As discussed above, mAbs can target solu-
ble or membrane bound antigens and their PD responses
could be driven through binding of the target antigen and
the corresponding downstream effects and/or by effector
functions such as ADCC and CDC. Depending on the mech-78 www.drugdiscoverytoday.comanism of action of the therapeutic mAb, types of PD responses
include inhibition of ligand-receptor interactions by binding
of mAbs to soluble targets, down-modulation of target anti-
gen by elimination of target cells, or impact on cell signaling
by blocking receptors [2]. In animal or human studies, PD
measurements could be directly or indirectly linked to a
clinical endpoint.
Translational PK/PD approaches for mAbs
Determining PK/PD relationships across species can help
understand how exposure drives response and then use that
to predict PK/PD in humans and determine optimal doses and
regimens for maximal clinical benefit. A basic framework for
translation of PK/PD of mAbs from in vitro and animal data to
humans is shown in Fig. 2. This includes getting appropriate
efficacy, safety, PK and PD data from in vitro and in vivo
studies, understanding exposure-response (PK/PD) relation-
ships, predicting human PK, and finally integrating the PK
data with efficacy and safety data to predict PK/PD in humans
to estimate first in human (FIH) and efficacious dose ranges in
patients. Some of the considerations for types of studies,
species selection, available tools, and modeling approaches
are discussed below.
Target biology and mAb molecular properties
Understanding the biology of target antigen, mechanism of
action of the mAb, and mAb-antigen interactions are impor-
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[2,3,8]. Types of information about target antigen that could
impact PK and PD include (i) expression levels, (ii) tissue
distribution patterns and which organs and tissues express it,
(iii) turnover kinetics in both plasma and various tissues, (iv)
whether it can be down-modulated or upregulated, (v) in case
of membrane bound targets, whether they can be shed, and
(vi) downstream signaling of the target. Aspects of the mAb
that are important to characterize are (i) binding affinity to
the target antigen, (ii) binding to Fc receptors such as FcRn
and FcgR, (iii) assessment of effector functions such ADCC
and CDC, (v) molecule characteristics such as charge, pI,
hydrophobicity, glycosylation, and (vi) preliminary assess-
ments of off-target binding using in-silico or in vitro methods
such as BV ELISA tools [26,27]. Binding affinity to target
antigen can greatly influence PK of mAbs and it is important
to obtain measurements of affinity or equilibrium dissocia-
tion constant (Kd), association rate constant (kon), and disso-
ciation rate constant (koff). The relationship between
antibody-antigen binding kinetics and antigen turnover ki-
netics is complex and there appears to be an optimal binding
affinity beyond which distribution of the mAb to target tissue
may be impaired [28,29]. Characterization of binding to FcRn
is also essential and as this is a pH dependent interaction,
binding affinity should be measured at both pH 6.0 (where
FcRn binds mAb in the acidic pH of the endosome) and pH
7.4 (physiological pH where FcRn releases mAb at the cell
surface). High binding to FcRn at pH 6.0 along with low
binding at pH 7.4 is essential for low clearance of mAbs
[17,18]. Several studies have investigated the correlation
between FcRn binding affinity and half-life of mAbs, and
the contribution of FcRn to prolonging the half-lives of mAbs
is well recognized, though this should be put in context of the
relative contribution of the FcRn pathway to total clearance
[17–19].
Species selection for PK, efficacy and safety studies
Studies to characterize the PK, PD, efficacy, and safety in
appropriate animal models are essential in understanding the
PK/PD characteristics of the molecule and then translating to
humans should be based on similarity of target antigen
properties, appropriate binding of mAb to target antigen
(i.e., binding species vs. non-binding species) and similar
pharmacology upon target binding [3,30]. However, PK/PD
of mAbs can be different in animals and human due to
differences in either target antigen such as target homology,
distribution, expression levels and turnover, or mAb proper-
ties such as differences in mAb-antigen binding or binding to
FcRn across species. For example, murine FcRn appears to
have a much higher affinity to human IgG than human FcRn,
while cynomolgus monkey FcRn has similar binding affinity
to human IgG as human FcRn [31,32]. Hence, cynomolgus
monkeys is typically the preferred species to evaluate PK ofmAbs for prediction of human PK. Recently, use of transgenic
mice that express human FcRn have been evaluated to assess
PK of mAbs and found to be promising [33,34]. In cases,
where mAbs do not bind to their target antigen in efficacy or
safety species, one approach could be using a surrogate anti-
body with suitable target-binding properties in the efficacy
and safety models. In addition to target antigen or FcRn
binding disparities, differences in off-target binding across
species resulting in different PK profiles have also been shown
for various mAbs. Examples include anti-FGFR (off-target
binding to mouse complement component 3), anti-Abeta
(off-target binding to fibrinogen in cynomolgus monkey),
and anti-NRP1 (possible off-target binding in mouse, rat,
human, but not cynomolgus monkey) [35–37]. Off-target
binding resulting in safety differences across species has been
reported, but is relatively rare [38,39]. For preclinical efficacy
studies, selection of appropriate animal models is dependent
on the ability to accurately recapitulate conditions of human
disease and ability to elicit similar mechanism of action of the
mAbs including target engagement, downstream pharmacol-
ogy and effector functions, which can be very challenging.
For example, human tumor xenografts implanted in mice are
the primary models used to evaluate anti-tumor efficacy, but
could have several differences from human tumors such as
faster growth rates, different vasculature, etc.
Immunogenicity
Administration of a therapeutic mAb into animals or humans
could result in the formation of anti-therapeutic antibodies
(ATA) that can bind to the mAb and form immune complexes
that could potentially impact the PK, safety, and efficacy of
mAbs. ATAs can be neutralizing (bind to epitopes on mAb
needed for biological activity) or non-neutralizing (bind to
epitopes not needed for activity) and can confound interpre-
tation of mAb characteristics [2,3,40]. Immunogenicity of
mAb varies across species due to the different human fraction
based on the type of therapeutic mAb (murine, chimeric,
humanized or fully human), and hence animals are not
predictive of human immunogenicity. PK profiles can be
altered by the presence of ATAs where serum concentrations
can suddenly drop due to increased clearance of the immune
complexes, as shown in Fig. 1. Approaches to handle this data
for PK analysis include excluding ATA-positive animals or
using data only until ATA develops and impacts the PK profile
[40]. Several groups have also evaluated mechanistic PK/PD
models that account for ATA impact on PK and PD [41–43].
Bioanalytical tools
There have been great advances in bioanalytical analytical
methods to measure concentrations of mAbs and their target
antigen in various matrices such as plasma, bile, tissues from
in vitro or in vivo studies. Multiple forms of the mAb and target
antigen can exist in various biological samples, such as freewww.drugdiscoverytoday.com 79
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Analytes that can be measured include free or bound forms of
mAb and target antigen and choice of analyte depends on
stage of drug development and type of information desired
[44]. As described in detail by Lee et al. [44], assessment of free
mAb can provide information on availability of mAb for free
target and its binding capacity, while total mAb (i.e., free plus
bound) can inform interactions between mAb and target. The
specificity of the bioanalytical assay is influenced by the ratio
of mAb to target and their dynamic equilibrium [44]. Com-
monly used methods are enzyme linked immunosorbent
assays (ELISAs) and more recently liquid chromatography-
mass spectrometry assays (LC-MS) [45,46]. Insights into spe-
cific and non-specific distribution of mAbs can be obtained
from radiolabeled biodistribution studies using tissue cut and
count techniques where the tissues are harvested at various
timepoints and radioactivity is measured [47,48]. Radioactive
probes commonly used include 125I-labeled antibody which
reflects tissue uptake kinetics, and 111In-DOTA labeled anti-
body, a residualizing probe that is charged and highly polar,
causing it to accumulate in cells if the labeled mAb is inter-
nalized. Other imaging technologies that can be used for
investigating in vivo biodistribution include single photon
emission computed tomography (SPECT) and positron emis-
sion tomography (PET) imaging [48].
Prediction of human PK/PD
Since PK of mAbs is dependent on PD, prediction of mAb PK
in humans needs to take into account both specific and non-
specific pathways of disposition. Several modeling
approaches are available to translate PK/PD of mAbs from
animals to humans and have been discussed in several
reviews and summarized below [5,49–52]. These can be
broadly categorized as (i) empirical approaches such allome-
try and species-invariant time methods, and (ii) mechanistic
approaches such as TMDD or physiologically based PK (PBPK)
models. More recently, advances are being made in new
approaches such as systems modeling that integrate systems
biology approaches with traditional PK/PD approaches to
attempt to understand the whole system in its entirety and
improve predictions [54–56].
Empirical approaches for prediction of human PK/PD
Several empirical approaches have been investigated for scal-
ing preclinical PK data of mAbs to humans [49,51]. These
approaches are largely based on allometric principles and
scaling uses a power model relating body weight and physio-
logical parameters of interest and can be expressed as
Y = aBWb, where Y is the parameter of interest, BW is the
body weight, a is the allometric coefficient, and b is the
allometric exponent. Important assumptions underlying al-
lometric scaling include linear PK and physiological, anatom-
ic, and biochemical similarity across species. There are several80 www.drugdiscoverytoday.comallometric methods including simple allometry (using multi-
ple species), simplified allometry (using only one species) and
allometric scaling with correction factors such as maximum
life span potential or brain weight [49]. Of all these methods,
simplified allometry using only cynomolgus monkeys to
scale to humans is the one that appears to provide the best
predictions and is recommended by most groups [49,51,52].
This is largely due to the similarity between cynomolgus
monkey and humans in terms of both antigen sequence
homology (target-mediated pathways) and FcRn binding
affinity (non-specific pathways). In addition, as discussed
previously, there are differences in mAb-FcRn binding affini-
ties across species that do not comply with the assumptions of
allometry and hence using multiple species may not be
appropriate.
For mAbs with linear PK, the two key PK parameters of
interest, clearance (CL) and volume of distribution (V), can be
reasonable scaled from cynomolgus monkeys to humans
using a fixed scaling exponent in the following equation:
Yhuman = Ycyno  (BWhuman/BWcyno)b, where Y is either CL or
V, BW is body weight, and b is the fixed scaling exponent [49].
For V, there is general agreement of using an exponent of 1,
based on the similarities across species of limited distribution
of mAbs to blood and extravascular spaces. For clearance
estimation, scaling exponents of 0.85 or 0.8 were proposed
by Deng et al. and Wang et al., respectively [51,56]. Two other
groups proposed an exponent of 0.85 for mAbs with soluble
antigens and 0.9 for mAbs with membrane bound antigens
[57,58]. All these scaling exponents provided reasonably
good clearance predictions from moneys to humans for the
set of mAbs evaluated by these groups. Additional PK param-
eters of interest after SC or IM dosing are rate and extent of
absorption and bioavailability. However, these processes are
likely influenced by multiple factors such FcRn binding,
presystemic catabolism, and injection site. Our understand-
ing of how to predict bioavailability from animals to humans
after SC administration is still lacking due to species differ-
ences in physiology of hypodermis, lymphatic system and
FcRn binding [3,7,49].
For mAbs with non-linear PK, the scaling of PK to humans
is not as straightforward due to considerations of target
antigen biology differences between animals and humans
such as target density, expression profiles, target turnover
kinetics, and affinity to the target. Human PK estimates have
been made in these cases by using a two-compartment PK
model with parallel linear and nonlinear elimination de-
scribed by the Michaelis–Menten equation to estimate mon-
key PK parameters followed by allometric scaling to estimate
human parameters [49,52]. An analysis on 6 mAbs with non-
linear PK was conducted by Dong et al. that showed good
prediction of area under the curve (AUC) but overestimation
of maximum concentration (Cmax) after SC administration
[52]. They concluded that the best predictive performance
Vol. 21–22, 2016 Drug Discovery Today: Technologies | Translational pharmacologywas obtained after doses had achieved target-saturating con-
centrations and PK was in the linear range.
In addition to simplified allometric scaling methods as
discussed above, another empirical approach commonly used
is the elementary species-invariant time method (or com-
monly known as elementary Dederick plots) which can pre-
dict human PK profiles from monkey PK profiles and is useful
for simulating different dosing regimens [49,51]. This meth-
od assumes that the dose-normalized drug concentration in
animals is equivalent to human and scales the PK time to
humans using the CL exponent obtained from simplified
allometry [51,59,60]. Similar to simplified allometry, this
method works well under conditions of mAb PK linearity
and should be used cautiously when mAb doses are in the
non-linear range.
To determine concentration-response relationships, tradi-
tionally empirical approaches such as the classic Hill equa-
tion have been used to obtain parameters such as Emax
(maximum effect), EC50 (drug concentration that produces
50% of Emax), and Hill coefficient (slope that reflects the
steepness of the concentration-response curve) [5]. Translat-
ing these parameters to humans is challenging and typically
they are assumed to be the same as in animals or scaled across
species using in vitro assays [50].
Mechanistic approaches for prediction of human PK/PD
Due to limitations of empirical methods for mAbs with non-
linear PK, more mechanistic methods such as TMDD and
PKPD models have been explored that take into account
physiological turnover and homeostasis of biological com-
ponents of the system [49]. As discussed previously, TMDD
describes drug whose disposition is influenced by binding to
the target and this is usually exhibited as a nonlinear depen-
dence on dose [6]. However, some challenges with using these
TMDD models are a lack of key data on the target and/or
mAb-target antigen complex levels that are needed for ap-
propriate parameter identifiability. In addition, PK data must
be available across a wide concentration range at different
levels of target saturation to allow discernment of the non-
linearity. Scaling of these model parameters to humans is
more complicated and human PK parameters are typically
scaled by simplified allometry, while human PD parameters
are either experimentally determined, scaled allometrically
from monkey parameters or assumed to be the same as
monkeys [49,61,62].
Another mechanistic approach is PBPK modeling which
integrates physiological and anatomical information with
drug specific information from in vitro and in vivo ADME data,
and can allow evaluation of system-specific and drug-specific
factors and facilitate translation from in vitro to in vivo as well
as across species [63]. While this has been used extensively
for small molecule, its utilization for large molecules is still at
an early stage. Due to its complexity compared with tradi-tional PK/PD models, its use has been limited in the devel-
opment of mAbs. Simplified approaches have been proposed
like minimal PBPK models that reduce the dimensions in the
model and make it easier to apply [49,63].
More recently, novel approaches such as systems pharma-
cology models are being investigated which incorporate sys-
tems biology concepts with those of PK/PD to aim to
understand the behavior of the whole system rather than
its individual components. This new systems pharmacology
approach has been reviewed in several recent publications
[53–55]. Briefly, PK/PD models are usually based on the
pharmacology of a single pathway whereas systems pharma-
cology models are much broader and can incorporate multi-
ple functional interactions within a biological network. This
offers the advantage of being able to describe complex pat-
terns of drug action and disease progression, scale across
species, and translate PK/PD behavior to humans.
Conclusions
Great strides have been made in improving our understand-
ing of the PK and PD of mAbs and factors that impact them.
However, many unresolved questions remain such as factors
influencing SC bioavailability, clear role of Fc receptors in
efficacy and biodistribution, prediction of immunogenicity,
influence on PK/PD of molecular properties such as charge,
hydrophobicity, glycosylation, and their interdependencies,
and scaling of PD parameters across species. While empirical
approaches for translational PK/PD are still commonly used
for mAbs with varying degrees of success, mechanistic
approaches are increasingly being used as more sophisticated
tools become available to generate relevant data. In addition,
exciting research is emerging in the nascent systems phar-
macology area. Advances in increasingly sophisticated bioa-
nalytical tools coupled with novel efficacy and safety models
as well as PK/PD and systems modeling approaches will serve
to increase the mechanistic understanding of PK/PD of mAbs
and have the potential to improve translatability, refine
choice of dose and regimens, inform suitable drug delivery
approaches and rationale drug combinations, and enable
greater probability of clinical success for novel therapeutic
mAbs.
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